Skip to main content
Top
Published in:

01-04-2023 | Cerebrovascular Diseases | Editor's Note

Is it possible to show a gene abnormality with an inherent macro morphology/function?

Author: Yoshiki Hirooka

Published in: Journal of Medical Ultrasonics | Issue 2/2023

Login to get access

Excerpt

According to the latest statistics on trends in death rates (per 100,000 population) for leading causes of death in Japan, the death rate due to malignant neoplasms exceeded that of cerebrovascular diseases in 1981 to take the top spot, after which it has continued to increase while maintaining that top spot by an overwhelming margin. It is a scientifically proven fact that people are more likely to develop malignant neoplasms as they grow older, so this is no surprise given Japan's declining birthrate and growing proportion of elderly people. In addition, the death rate due to senility exceeded that of cerebrovascular diseases in 2018. The current leading causes of death in Japan are malignant neoplasms at number one, heart diseases excluding hypertension at number two, and senility at number three. …
Metadata
Title
Is it possible to show a gene abnormality with an inherent macro morphology/function?
Author
Yoshiki Hirooka
Publication date
01-04-2023
Publisher
Springer Nature Singapore
Published in
Journal of Medical Ultrasonics / Issue 2/2023
Print ISSN: 1346-4523
Electronic ISSN: 1613-2254
DOI
https://doi.org/10.1007/s10396-023-01314-x

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest